Atractylenolide III alleviates MASLD by inhibiting lipid synthesis and apoptosis via PTEN.
BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global health issue. This study aims to investigate the ameliorative effects of atractylenolide III (ATL III) on MASLD and its underlying molecular mechanisms, thereby providing theoretical basis and experimental support...